Please use this identifier to cite or link to this item:
http://repository.pdmu.edu.ua/handle/123456789/8673| Title: | Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study |
| Authors: | Weinblat, M. Baranauskaite, A. Niebrzydowski, J. Dokoupilova, E. Zielinska, A. Sitek-Ziolkowska, K. Jaworski, J. Racewicz, A. Pileckyte, M. Jedrychowicz-Rosiak, K. Zhdan, V. Cheong, SY. Ghil, J. Ждан, Вячеслав Миколайович |
| Issue Date: | 13-Nov-2016 |
| Publisher: | American College of Rheumatology |
| Citation: | Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study[Електронний ресурс] /M. Weinblatt, A. Baranauskaite, J. Niebrzydowski [at al.] // American College of Rheumatology. November 13, 2016. Режим доступу до журн.: https://acrabstracts.org/abstract/sustained-efficacy-and-comparable-safety-and-immunogenicity-after-transition-to-sb5-an-adalimumab-biosimilar-vs-continuation-of-sb5-or-reference-adalimumab-humira-in-patients-with-rheumatoi |
| Keywords: | biosimilars |
| URI: | http://repository.pdmu.edu.ua/handle/123456789/8673 |
| Appears in Collections: | Наукові праці. Кафедра сімейної медицини і терапії |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| EfficacySafetySB5Adalimumab_RheumatoidArthritis.pdf | 83,71 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.